Sitagliptin Treatment After Total Pancreatectomy With Islet Autotransplantation: A Randomized, Placebo-Controlled...

Area of Science:

• Endocrinology
• Gastroenterology
• Transplantation Surgery

Background:

• Total pancreatectomy and islet autotransplant (TPIAT) for chronic pancreatitis often results in limited insulin independence due to beta cell apoptosis.
• Incretin hormones like GLP-1 and GIP may protect beta cells, and their levels can be increased by dipeptidyl peptidase 4 (DPP-4) inhibitors such as sitagliptin.

Purpose of the Study:

• To investigate the effect of sitagliptin on metabolic outcomes, specifically insulin independence, in adult patients following TPIAT.
• To assess the safety and efficacy of sitagliptin in preserving beta cell function post-TPIAT.

Main Methods:

• A randomized controlled trial involving 83 adult TPIAT recipients.
• Participants received either sitagliptin (n=54) or placebo (n=29) for 12 months post-TPIAT.
• Evaluations at 12 and 18 months included insulin independence assessment, mixed meal tolerance tests, and frequent sample intravenous glucose tolerance tests.

Main Results:

• No significant difference in insulin independence rates between the sitagliptin and placebo groups at 12 months (42% vs. 45%) or 18 months (36% vs. 44%).
• Similar insulin doses, Hemoglobin A1c levels, and insulin secretory measures were observed in both groups.
• Sitagliptin was safely administered, with comparable adverse event profiles between the groups.

Conclusions:

• Sitagliptin administration following TPIAT is safe but does not improve insulin independence or other key metabolic outcomes.
• The potential protective effects of DPP-4 inhibitors on beta cells may not translate to improved clinical outcomes in this specific patient population.